Pfizer Pre-Tax Income 2012-2026 | PFE
Pfizer annual/quarterly pre-tax income history and growth rate from 2012 to 2026. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Pfizer pre-tax income for the quarter ending March 31, 2026 was $3.170B, a 13.82% increase year-over-year.
- Pfizer pre-tax income for the twelve months ending March 31, 2026 was $7.906B, a 7.03% increase year-over-year.
- Pfizer annual pre-tax income for 2025 was $7.52B, a 6.27% decline from 2024.
- Pfizer annual pre-tax income for 2024 was $8.023B, a 658.32% increase from 2023.
- Pfizer annual pre-tax income for 2023 was $1.058B, a 96.95% decline from 2022.
|
Pfizer Annual Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2025 | $7,520 |
| 2024 | $8,023 |
| 2023 | $1,058 |
| 2022 | $34,729 |
| 2021 | $24,311 |
| 2020 | $7,036 |
| 2019 | $11,321 |
| 2018 | $3,594 |
| 2017 | $12,305 |
| 2016 | $8,351 |
| 2015 | $8,965 |
| 2014 | $12,240 |
| 2013 | $15,716 |
| 2012 | $11,242 |
| 2011 | $11,481 |
|
Pfizer Quarterly Pre-Tax Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $3,170 |
| 2025-12-31 | $-1,642 |
| 2025-09-30 | $3,334 |
| 2025-06-30 | $3,044 |
| 2025-03-31 | $2,785 |
| 2024-12-31 | $-10 |
| 2024-09-30 | $4,715 |
| 2024-06-30 | $-103 |
| 2024-03-31 | $3,421 |
| 2023-12-31 | $-4,129 |
| 2023-09-30 | $-3,352 |
| 2023-06-30 | $2,269 |
| 2023-03-31 | $6,270 |
| 2022-12-31 | $5,231 |
| 2022-09-30 | $9,001 |
| 2022-06-30 | $11,447 |
| 2022-03-31 | $9,050 |
| 2021-12-31 | $3,827 |
| 2021-09-30 | $7,843 |
| 2021-06-30 | $6,949 |
| 2021-03-31 | $5,692 |
| 2020-12-31 | $598 |
| 2020-09-30 | $570 |
| 2020-06-30 | $3,026 |
| 2020-03-31 | $2,842 |
| 2019-12-31 | $-7,870 |
| 2019-09-30 | $10,727 |
| 2019-06-30 | $4,141 |
| 2019-03-31 | $4,323 |
| 2018-12-31 | $-9,237 |
| 2018-09-30 | $4,177 |
| 2018-06-30 | $4,527 |
| 2018-03-31 | $4,127 |
| 2017-12-31 | $954 |
| 2017-09-30 | $3,585 |
| 2017-06-30 | $3,815 |
| 2017-03-31 | $3,951 |
| 2016-12-31 | $776 |
| 2016-09-30 | $1,604 |
| 2016-06-30 | $2,410 |
| 2016-03-31 | $3,561 |
| 2015-12-31 | $-353 |
| 2015-09-30 | $2,697 |
| 2015-06-30 | $3,539 |
| 2015-03-31 | $3,082 |
| 2014-12-31 | $1,803 |
| 2014-09-30 | $3,587 |
| 2014-06-30 | $4,003 |
| 2014-03-31 | $2,847 |
| 2013-12-31 | $3,061 |
| 2013-09-30 | $3,573 |
| 2013-06-30 | $5,357 |
| 2013-03-31 | $3,725 |
| 2012-12-31 | $1,821 |
| 2012-09-30 | $2,806 |
| 2012-06-30 | $4,180 |
| 2012-03-31 | $2,435 |
| 2011-12-31 | $1,224 |
| 2011-09-30 | $3,541 |
| 2011-06-30 | $3,598 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |